RDNT RadNet, Inc.

NEUTRAL Impact: 4/10 8-K
Horizon weeks Filed Jun 3, 2026 Processed 11d 20h ago SEC 0001683168-26-004475
8-K context-dependent: Items 8.01
Latest settled — T+1d
RDNT ▲ +1.81% at T+1d
NEUTRAL call ✓ call won +1.81% · α vs SPY +1.41% · entry $51.87 → $52.81
Next anchor: T+5d due 5d ago
Last close $56.71 (close Jun 12) · +9.33% from $51.87 entry
Entry anchored
Jun 2, 03:59 PM ET
via Databento tick
T+1d
+1.81%
call +1.81% · α +1.41%
$52.81
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

RadNet announced a proposed $200 million incremental term loan under its existing first lien credit agreement, with proceeds earmarked for future acquisitions, organic expansion, health system partnerships, and general corporate purposes. The loan would mature in April 2031, matching the existing term loan maturity. The transaction is subject to customary conditions and expected to close mid-June 2026.

Actionable Insight

The $200 million incremental term loan provides RadNet with additional firepower for M&A and growth initiatives, but also increases leverage. Monitor for acquisition announcements and the final interest rate spread when the amendment is consummated. The stock's reaction will depend on whether the market views this as accretive growth funding or balance sheet strain.

Key Facts

  • Proposed $200 million incremental term loan under existing first lien credit agreement
  • Loan would mature April 18, 2031, coincident with existing term loan maturity
  • Proceeds to fund future acquisitions, organic expansion, health system partnerships, and general corporate purposes
  • Transaction subject to customary market and other conditions; expected to close mid-June 2026
  • No pricing or interest rate terms disclosed in the filing

Financial Impact

$200 million incremental debt added to existing term loan facility

debtleverage

Risk Factors

  • Increased leverage and interest expense from additional $200 million in debt
  • Execution risk on deploying proceeds accretively for acquisitions or organic growth
  • Potential for unfavorable pricing or covenants in the final amendment terms

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
93% bullish (14 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001683168-26-004475
Document: 0001683168-26-004475-index.html0001683168-26-004475
Document: 0001683168-26-004475.txt0001683168-26-004475
11 reports for RDNT
Performance horizon
40% Hit rate 2 of 5 directional calls best @ T+5▲ +1.95%Apr 28, 2026
Filters
Rows
Reports for RDNT — sortable, filterable
Type Now
Jun 10, 2026
4d ago
8-K
NEUTRAL ★ 5/10
$58.19 awaiting T+1awaiting T+1$56.71 (−2.54%)
Jun 3, 2026
11d ago
8-K
NEUTRAL ★ 4/10
$51.87 $52.81▲ +1.81%▲ +1.41%$56.71 (+9.33%)
May 11, 2026
4w ago
8-K
MIXED ★ 6/10
$55.90 $56.00▲ +0.18%▲ +0.32%$56.71 (+1.45%)
May 10, 2026
5w ago
Press Release
BULLISH ★ 7/10
$55.90 $56.00▲ +0.18%▲ +0.32%$56.71 (+1.45%)
Apr 28, 2026
6w ago
Press Release
BULLISH ★ 7/10
$57.89 $55.89▼ −3.45%▼ −3.44%$56.71 (−2.04%)
Apr 20, 2026
7w ago
DEFA14A
NEUTRAL ★ 3/10
$57.51 $57.83▲ +0.56%▼ −0.46%$56.71 (−1.39%)
Mar 11, 2026
13w ago
Press Release
NEUTRAL ★ 3/10
$59.78 $62.09▲ +3.86%▲ +4.46%$56.71 (−5.14%)
Mar 4, 2026
14w ago
Press Release
BULLISH ★ 7/10
$71.33 $66.67▼ −6.53%▼ −5.96%$56.71 (−20.50%)
Mar 2, 2026
14w ago
Press Release
NEUTRAL ★ 3/10
$75.22 $72.58▼ −3.51%▼ −2.60%$56.71 (−24.61%)
Mar 2, 2026
14w ago
Press Release
BULLISH ★ 8/10
$75.22 $72.58▼ −3.51%▼ −2.60%$56.71 (−24.61%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 5h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access